Overview

Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Resolute Stents Implantation; C-MODE Trial

Status:
Not yet recruiting

Trial end date:
2025-07-10

Target enrollment:
0

Participant gender:
All

Summary

Previous randomized clinical trials have deomonstrated the efficacy and safety of short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), however, the single antiplatelet agent to be maintained after short-term DAPT was different. Therefore, which antiplatelet agent to be maintained after short-term DAPT needs further invstigations.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Yonsei University

Treatments:

Aspirin
Clopidogrel

Criteria

Inclusion Criteria:

1. Patients ≥19 years

2. Patients who received new generation zotarolimus-eluting stent (Resolute Onyx ®)
stents implantation for treating ischemic heart disease

3. Provision of informed consent

Exclusion Criteria:

1. Age ≥ 85 years

2. Acute myocardial infarction

2. Left main bifurcation requiring 2-stent technique 3. Pregnant women or women with
potential childbearing 4. Life expectancy < 1 year 5. Inability to follow the patient over
the period of 1 year after enrollment, as assessed by the investigator 6. Inability to
understand or read the informed consent